Probiomics
Private Company
Funding information not available
Overview
Probiomics is a Milan-based, private biotechnology service provider that operates at the intersection of experimental omics assays and advanced bioinformatics. Leveraging technologies from partners like Olink, Oxford Nanopore, and Fluidigm, the company offers a comprehensive suite of services for generating and analyzing genomic, transcriptomic, proteomic, and epigenetic data. Its core value proposition is the integration of multiple omics layers to provide clients with a holistic view of biological systems, supported by a proprietary web platform and a multidisciplinary team. The company appears to be in an early-revenue stage, serving research clients and developing its 'Re-Clinic' project with regional grant support.
Technology Platform
Integrated multi-omics service platform combining third-party experimental technologies (Olink, Oxford Nanopore, Fluidigm) with proprietary bioinformatics and data integration software for genomics, transcriptomics, proteomics, and epigenomics.
Opportunities
Risk Factors
Competitive Landscape
Probiomics competes in a crowded field of omics service providers, including university core facilities, large commercial CROs (e.g., Eurofins, Charles River), and specialized boutique bioinformatics firms. Its key differentiator is the explicit integration of multiple omics layers with a proprietary analysis platform, a niche that requires rare cross-disciplinary expertise but also faces slower market adoption than single-omics services.